Mallinckrodt has started patient recruitment in a Phase IIa clinical trial of MNK-6106 (L-ornithine phenylacetate) for the treatment of hepatic (liver) cirrhosis and hepatic encephalopathy (HE).
July’s top news stories Eli Lilly reported positive findings from the Phase III MONARCH 2 clinical trial of Verzenio (abemaciclib) with fulvestrant to treat advanced or metastatic breast cancer.
Projects
Emflaza (deflazacort) for the Treatment of Duchenne Muscular Dystrophy Emflaza™ (deflazacort) is the first glucocorticoid drug approved in the US for treatment of patients aged two years and older suffering from duchenne muscular dystrophy (DMD). The drug was discovered and developed by Marathon Pharmaceuticals.
Sometimes, You Have to Move to Go Forward PhenoSwitch Biosource is proud to announce that it will be operating from a new space in the beautiful Sherbrooke, Quebec, Canada.
Immunoassay Technology Gyrolab users regard this system as a must-have technology for accelerating biopharmaceutical development and production.
Getting Acquainted with the Theory of XRF This white paper provides a general introduction to X-ray Fluorescence (CRF) spectrometry and XRF analysis. It explains how a spectrometer works and how XRF analysis is achieved.
Thanks for reading. If you enjoyed this newsletter, please share with colleagues, friends and anybody else, get them to sign up and join the conversation. You can contact us at marketing@verdict.co.uk.
Up-to-date international news and features on the Healthcare industry
You are receiving this email because you are either a valued subscriber to Verdict Drug Development Technology or have signed up via a partner website. Your email address has not been, and will not be, given to third parties.